News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
237,058 Results
Type
Article (7945)
Company Profile (54)
Press Release (229059)
Section
Business (65198)
Career Advice (366)
Deals (12707)
Drug Delivery (29)
Drug Development (26630)
Employer Resources (33)
FDA (7706)
Job Trends (6292)
News (114353)
Policy (10503)
Tag
Academia (767)
Alliances (21089)
Alzheimer's disease (469)
Approvals (7687)
Artificial intelligence (96)
Bankruptcy (78)
Best Places to Work (5836)
Breast cancer (83)
Cancer (649)
Cardiovascular disease (60)
Career advice (322)
Cell therapy (110)
Clinical research (22974)
Collaboration (307)
COVID-19 (739)
C-suite (52)
Data (696)
Diabetes (64)
Diagnostics (3203)
Earnings (22858)
Events (29763)
Executive appointments (188)
FDA (8113)
Funding (220)
Gene therapy (94)
GLP-1 (202)
Government (1438)
Healthcare (7392)
Infectious disease (782)
Interviews (43)
IPO (5302)
Job creations (716)
Job search strategy (271)
Layoffs (66)
Legal (1640)
Lung cancer (111)
Lymphoma (60)
Manufacturing (116)
Medical device (7428)
Medtech (7431)
Mergers & acquisitions (7582)
Metabolic disorders (155)
Neuroscience (617)
NextGen: Class of 2025 (2787)
Non-profit (1226)
Northern California (721)
Obesity (80)
Opinion (57)
Parkinson's disease (49)
Patents (44)
People (16767)
Phase I (6590)
Phase II (9842)
Phase III (8511)
Pipeline (233)
Postmarket research (948)
Preclinical (1247)
Radiopharmaceuticals (98)
Rare diseases (114)
Real estate (1986)
Regulatory (8100)
Research institute (765)
Resumes & cover letters (56)
Southern California (590)
Startups (1100)
United States (6639)
Vaccines (138)
Weight loss (59)
Date
Last 7 days (317)
Last 30 days (825)
Last 365 days (14536)
2025 (680)
2024 (14718)
2023 (16402)
2022 (22508)
2021 (23801)
2020 (23591)
2019 (20847)
2018 (15112)
2017 (12203)
2016 (11181)
2015 (12429)
2014 (8943)
2013 (7358)
2012 (7812)
2011 (7826)
2010 (6310)
Location
Africa (182)
Arizona (58)
Asia (13200)
Australia (1806)
California (1611)
Canada (535)
China (148)
Colorado (91)
Connecticut (76)
Delaware (57)
Europe (33386)
Florida (219)
Georgia (83)
Illinois (196)
Indiana (173)
Japan (47)
Maryland (238)
Massachusetts (1048)
Michigan (103)
Minnesota (185)
New Jersey (522)
New York (486)
North Carolina (384)
Northern California (721)
Ohio (76)
Pennsylvania (385)
South America (349)
Southern California (590)
Texas (215)
Utah (46)
Virginia (48)
Washington State (119)
237,058 Results for "loftware enterprise labeling solutions".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
QuantHealth Expands Its Leadership Team, Primes its SaaS Platform for Enterprise-Grade Pharmaceutical Partnerships
January 13, 2025
·
4 min read
Press Releases
Cencora Expands Enterprise Leadership Team with Two Senior Appointments
November 5, 2024
·
3 min read
Prostate cancer
Pfizer Phase III Prostate Cancer Win Builds Case for Broader Label for Talzenna-Xtandi Combo
The overall survival data from the late-stage trial will help Pfizer in its bid to expand the label for Talzenna and Xtandi, potentially covering all patients with metastatic castration-resistant prostate cancer regardless of biomarker status.
October 10, 2024
·
2 min read
·
Tristan Manalac
Drug Development
Enterprise Therapeutics Publishes Preclinical Profile of ETD001, a Novel Inhaled ENaC Blocker
Enterprise Therapeutics Ltd, a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of people with respiratory diseases, announced the publication of a peer reviewed study in the Journal of Cystic Fibrosis.
June 12, 2024
·
2 min read
Press Releases
First Ascent Biomedical Secures $6 Million Investment from Vidal Duart Enterprises, Inc. to Revolutionize Cancer Treatment
January 13, 2025
·
4 min read
Harrow Announces 52-Week Data from VEVYE® ESSENCE-2 Open-Label Extension Study
Harrow is pleased to announce results from its ESSENCE‑2 open-label extension (OLE) clinical study for VEVYE® (cyclosporine ophthalmic solution) 0.1%, the first and only cyclosporine to treat the signs and symptoms of dry eye disease (DED).
June 5, 2024
·
8 min read
Pharm Country
Food And Drug Administration Grants Two New Label Changes To Tirosint®-Sol (Levothyroxine Sodium) Oral Solution
The U.S. Food and Drug Administration (FDA) has approved two new changes to the label of Tirosint-SOL (levothyroxine sodium) oral solution, a unique formulation of levothyroxine (LT4) for the treatment of hypothyroidism.
December 4, 2023
·
8 min read
Approvals
FDA Approves Atopic Dermatitis Label Expansion for Arcutis’ Zoryve Cream
The regulator Tuesday added atopic dermatitis to the label of Arcutis Biotherapeutics’ topical PDE4 inhibitor Zoryve for the treatment of patients six years of age and older.
July 10, 2024
·
2 min read
·
Tristan Manalac
Approvals
GSK Wins Broad Label Expansion for Jemperli in First-Line Endometrial Cancer
In pursuit of Merck’s blockbuster Keytruda, GSK’s Jemperli scored its own broad FDA label expansion, allowing its use in first-line endometrial cancer regardless of biomarker status.
August 2, 2024
·
2 min read
·
Tristan Manalac
Press Releases
VIVUS Announces Label Update for QSYMIA®
October 24, 2024
·
10 min read
1 of 23,706
Next
